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Abstract
This manuscript provides nomenclature recommendations developed by an international 
workgroup to increase transparency and standardization of pharmacogenetic (PGx) result 
reporting. Presently, sequence variants identified by PGx tests are described using different 
nomenclature systems. In addition, PGx analysis may detect different sets of variants for each 
gene, which can affect interpretation of results. This practice has caused confusion and may 
thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx 
forward.
Keywords
Pharmacogenetic PGx testing; nomenclature; test result reporting; variant description
BACKGROUND
Individuals vary considerably in their response to medications. Some patients show a 
substantial therapeutic response to a given drug, while others may not. In addition, certain 
patients may require considerably higher or lower doses of a drug to achieve maximum 
benefit or to avoid an adverse reaction (1-3). Many factors contribute to this variability, 
including sex, age, diet, environmental exposures (e.g., toxic chemicals or cigarette smoke), 
inflammation-induced phenoconversion (4), epigenetic signatures, and drug interactions. 
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The recognition that part of this variation in patient response may be genetic, and therefore 
potentially predictable, led to the development of numerous PGx tests to assess the presence 
or absence of known genetic variants to help predict an individual’s response to drugs (5). 
The results of these tests can help healthcare providers to select the most effective drug(s) 
and doses for a patient, inform drug development, and/or stratify participants in clinical 
trials (6, 7).
Research studies have identified over 1000 human genes that may affect drug response (8). 
Clinically relevant PGx interactions typically involve genes related to absorption, 
distribution, metabolism and excretion of a drug (ADME) (9), or genes that encode drug 
targets and other proteins involved in the drug’s mechanism of action. For example, non-
ADME genes such as CFTR and VKORC1 are relevant to ivacaftor and warfarin response, 
respectively, and may be tested to guide therapeutic decision-making. In addition, genes 
encoding the human leukocyte antigens (HLA) are commonly tested for the variant HLA-
B*57:01 to predict the likelihood of hypersensitivity reactions for abacavir (10) in patients 
seeking human immunodeficiency virus (HIV) antiretroviral therapy.
In 2015, about 150 different drugs that are approved by the US Food and Drug 
Administration (FDA) include pharmacogenetic information in the label, and only a few of 
them have recommendations for PGx testing (11). Similarly, 155 drugs have PGx 
information in their Summary of Product Characteristics (SPC) as defined by the European 
Medicines Agency (EMA) (12). Both the FDA label and the EMA SPC contain information 
ranging from references to pharmacokinetic genes or drug targets to requirements for 
genetic testing. However, labels mentioning genetic testing are rare and often associated 
with drugs for cancer treatment (e.g., EGFR/afatinib, ALK/crizotinib, KRAS/panitumumab). 
Other examples of established gene/drug associations include HLA-B/abacavir, HLA-B/
carbamazepine, CYP2C19/clopidogrel, CYP2D6/Codeine, POLG/valproate, G6PD/
rasburicase, TPMT/thiopurines, and others. Although many of these drugs are widely 
prescribed (13), for most of them PGx testing has yet to become common practice.
At the current time, clinical laboratories offer testing for a number of PGx genes, including 
CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, HLA-B*57:01, SLCO1B1, 
VKORC1, and TPMT. The National Institutes of Health (NIH) Genetic Testing Registry (14, 
15) lists over 280 PGx tests for about 160 drug responses. While some laboratories that offer 
these tests have reported good success with respect to feasibility and acceptance of genetic 
testing (16), others have suggested that PGx tests are underutilized (17-19). Lack of 
acceptance can arise when clinicians do not have sufficient knowledge of PGx tests, are 
unable to obtain the test results within an appropriate turn-around time (20), are not sure 
whether there is sufficient evidence to support the use or reimbursement of PGx tests 
(20-22), or cannot interpret and translate the genotype information into clinical actions (19, 
23, 24).
Ideally, test results and interpretations should be consistent regardless of which clinical 
laboratory performs the analysis. However, laboratories differ with respect to the PGx 
variants and haplotypes that are tested and the manner in which results are interpreted and 
communicated to the prescriber. This variability can have a significant impact on clinical 
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decision-making, particularly because many genes involved in ADME and other aspects of 
pharmacology and toxicology can vary considerably among individuals and populations (25, 
26). As such, standardized nomenclature and transparency of variants tested and used for 
PGx haplotype definitions are needed to advance the adoption of pharmacogenetic testing by 
clinicians and to ensure that prescribers have essential information for appropriate treatment 
decisions.
Overview of Nomenclature for PGx Genes
Activity or function of enzymes, transporters or drug targets (pharmacogenetic phenotype) 
can be predicted by testing for one or more known sequence variants in PGx genes. Variants 
or combinations of variants in a gene that are linked together on a single chromosome define 
haplotypes. The terms haplotype, allele, and allelic variation are often used interchangeably. 
Results of PGx tests are commonly reported as diplotypes (or haplotype pairs) since human 
genes are present in two copies, except for genes located on the non-homologous parts of the 
X and Y chromosomes in males. However, haplotypes or diplotypes are typically assigned 
based on genotypes of tested genetic variants, and default assignments may be applied 
depending on whether these variants are detected. The summarization of observed variants 
into alleles/haplotypes facilitates the association of diplotypes with predicted phenotypes. 
Many PGx genes have greater clinical relevance when low-function variants are viewed as 
conferring recessive rather than co-dominant or dominant phenotypic effects, and 
prescribing guidelines often differ substantially for individuals carrying two variant alleles 
compared to those carrying only one dysfunctional allele.
Variants found during DNA sequence analysis or other types of genotyping tests used to 
diagnose inherited or somatic disorders are named using Human Genome Variation Society 
(HGVS) nomenclature (27). The HGVS nomenclature had been designed specifically for 
use in clinical diagnostics and is currently the standard world-wide. Use of HGVS is 
recommended for clinical diagnostic reporting (28). This nomenclature system describes 
variants with respect to a reference sequence, making the genomic position of the variant 
and the changes to the DNA, RNA and protein sequences comprehensible and less 
ambiguous to current and future users of the information. The HGVS nomenclature does not 
specify a specific reference sequence, thus the same variant could be described using 
different reference sequences, which might cause confusion.
Unlike other genes, a variety of nomenclature systems have been developed to describe 
allelic variation and haplotypes of ADME genes (29). The most common is the “star” (*) 
system, which was implemented in the 1990s and has been widely adopted in the field. In 
most cases, *1 denotes the default reference (wild type or fully functional) allele or 
haplotype, while other designations (e.g. *2 or *3) define haplotypes carrying one or more 
variants (30). The *1 allele definition is usually based on the subpopulation in which the 
gene was initially studied, and may not necessarily indicate the most common allele in all 
populations. In some cases, *1 is not the reference allele; for example, NAT2*4 is the 
reference allele for the NAT2 gene as it is the most common functional allele across human 
populations (31, 32).
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Laboratories report a variant if one or more allele-defining sequence variations are found 
and default to a reference allele (often, but not always *1) assignment in their absence. It 
should be noted that the reference allele designation is assigned depending on which variants 
were assayed and consequently excluded, but does not consider variants not included in the 
assay (i.e., an assigned *1 carrier may still have variants that the test was not designed to 
detect). In other words, a negative result for the alleles interrogated by the assay (and the 
designation of the *1 haplotype or reference allele) does not exclude the possibility that 
other dysfunctional alleles may be present. The probability that a *1 or reference allele 
default assignment is correct increases with the number of relevant sequence variations 
tested.
Lists of haplotypes and nomenclature for PGx genes can be found on a variety of gene or 
gene family specific websites that are usually maintained by specific nomenclature 
committees (Table 1). Information about PGx haplotypes is also available through more 
comprehensive sites, including the Pharmacogenomics Knowledge Base (PharmGKB) (33). 
For many PGx genes (e.g. VKORC1), there are no nomenclature committees. In some 
instances, such SLCO1B1 (34) and ABCB1 (35), tables summarizing variation have been 
published, but are not systematically maintained. Furthermore, variants of many PGx genes, 
including VKORC1, may be reported using more than one nomenclature system (36, 37).
Rationale for Developing a Standard PGx Nomenclature
A major obstacle for the use of PGx information in clinical practice is the complexity of 
nomenclature systems and test designs, which can cause discrepancies in the predicted 
phenotype that is inferred from the genotype determined by the genetic test. Nomenclature 
differences contribute to difficulties reconciling genotype results for the same sample across 
laboratories (38, 39) and impede data analysis. Differences in test design can also lead to 
discordant diplotype results and ultimately incorrect phenotype predictions (Robert 
Freimuth, personal communication). As such, a standardized PGx nomenclature system that 
clearly describes the variants identified as well as increased transparency about the test 
design are crucial to advance the adoption of PGx testing by clinicians.
Comparing PGx testing results from different laboratories can be challenging. For example, 
the Centers for Disease Control and Prevention’s (CDC) Genetic Testing Reference Material 
Coordination Program (40) conducted projects to characterize genomic DNA samples from 
the Coriell Cell Repositories which can be used as reference materials for clinical PGx 
genetic testing (38, 39). During the most recent study, nine volunteer clinical, research and 
commercial laboratories were provided with blinded genomic DNA samples which were 
tested for a number of PGx genes using a variety of different methods including single 
nucleotide variant (SNV) genotyping, copy number variant (CNV) assessment, and DNA 
sequence analysis.
The results of the GeT-RM study illustrate many inconsistencies due to different 
nomenclature systems and PGx test designs. The participating laboratories employed 
varying terms to describe SNV genotype results for 28 PGx genes. The star nomenclature 
system was used by some laboratories to describe alleles/haplotypes of many of the tested 
genes, while other laboratories utilized the predicted amino acid change or various other 
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notations and/or nomenclatures. In many cases, laboratories described the detected sequence 
variations using several different nomenclature systems for the same genes (e.g. VKORC1, 
Table 2).
Furthermore, the GeT-RM study found inconsistencies in reporting of genotype results. 
Some of the DNA sequencing assays made genotype calls from the coding strand while 
others made calls from the based on the non-coding strand using the Human Genome 
Reference Assembly as a guide. One test did not use the Human Genome Reference 
Assembly, but instead used sequences representing the major alleles identified during the 
Hap Map project (Figure 1). These differences may not affect the actual results, but could 
impact the way in which results are represented and the depiction of variants in databases 
and scientific literature.
The tests performed in the GeT-RM study also showed little consistency in design. No two 
of the seven test panels detected the same set of SNVs/ haplotypes for any of the 28 PGx 
genes studied (39). Different haplotype calls were often made for the same allele in a given 
sample, because not all tests were designed to detect the same haplotypes, as illustrated in 
Table 2. In some cases these differences in test design can cause incorrect genotype 
assignments and phenotype prediction. As exemplified in Figure 2, the CYP2C19 phenotype 
may not be accurately predicted when only a subset of relevant SNVs is tested. An 
intermediate metabolizer would be misclassified as an ultra-rapid or extensive metabolizer if 
rs28399504 (NG_008384.2:g.5001A>G, NM_00769.1:c.1A>G), which defines the 
CYP2C19*4 haplotype, was not tested.
Inconsistencies in nomenclature and design of assay panels create unnecessary complexity 
and make it difficult to compare data from different genotyping platforms. This has been 
observed in clinical proficiency testing surveys. Participants in the College of American 
Pathologists Pharmacogenetic Proficiency Survey (PGX) often reported inaccurate 
genotypes and phenotypes due to differences in test design (41). For example, one of the 
CYP2D6 assays did not include any of the SNVs commonly used to identify the *41 allele. 
The results from this test could cause this allele to be classified as normal function (*1) 
rather than reduced function (*41). In addition, approximately half of the tests in the study 
were not designed to detect the increased function allele CYP2C19*17, and incorrectly 
called the proficiency testing samples CYP2C19*1 (normal function) (41).
Discrepancies may also arise due to the variable inclusion of methods to assess copy number 
variations. For example, tests that do not interrogate structural variants of CYP2D6 may 
report an individual with a CYP2D6*1/*2 haplotype as an extensive metabolizer, while 
another assay, that includes copy number assessment, may report the same genotype as an 
ultra-rapid metabolizer if a gene duplication is detected (e.g. CYP2D6*1/*2xN or *1xN/*2). 
These differences make it very difficult not only to understand genotype results, but also to 
compare results generated by different laboratories and/or tests. Such discrepancies may 
cause confusion, misinterpretation and incorrect results to be communicated; thus it is clear 
that standardized nomenclature, transparency of variants tested and unambiguous haplotype 
definitions are needed.
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Discrepancies in PGx testing and reporting may also cause other wide ranging effects. For 
example, inconsistencies in nomenclature or test design could affect clinicians’ ability to 
understand results from different laboratories and in the scientific literature, and may 
hamper decision making. Correct and unambiguous results are also important for the 
patient’s medical record, as these results may follow a patient for a lifetime. Payers often 
consider genetic testing to be a singular event that will not be repeated for the same gene as 
they usually do not expect the genetic result to change with time. This can affect test 
reimbursement if tests need to be reordered because the results cannot be interpreted or used 
for subsequent drug selection/dosing. These barriers hinder clinical adoption of PGx testing. 
Standardization of nomenclature is also critical for the accurate accumulation of data in 
clinical databases, such as ClinVar (42), gene variant databases such as the Leiden Open 
Variation Database (43), and PharmGKB.
To date, most PGx tests have evaluated the presence or absence of a defined set of known 
variants. However, next generation sequencing (NGS) is becoming more common in clinical 
and research laboratories and is also being applied to PGx testing. Sequence analysis will 
identify rare and/or novel variants with unknown or uncertain function that complicate not 
only allele designation and genotype calling, but also the prediction of phenotype (44). 
Recent results from numerous whole genome and whole exome sequencing efforts (e.g. the 
NHLBI GO Exome Sequencing Project (45), revealed the presence of many rare variant 
alleles in genes relevant to drug metabolism and transport, often missense in nature, which 
are not included in the current PGx databases (46). In addition, many more rare variants are 
expected to be identified during ongoing large population sequencing studies, including the 
100,000 Genomes project in the UK and the 1-Million-Genomes Project in the US. 
Consideration of these rare variants will be required for the advancement of precision 
medicine initiatives. It will be difficult to develop new haplotype designations for these 
recently identified variants using the existing star or other nomenclature systems, and 
therefore, it may be desirable to modify or discontinue the use of star allele nomenclature 
and instead describe PGx variants with the same naming conventions and systems used for 
other genes (47). It is expected that DNA sequencing of PGx associated genes will 
eventually become the standard method for genotype determination, which makes the 
creation of a standard variant naming format even more critical.
This manuscript describes consensus recommendations from an international workgroup 
composed of a variety of stakeholders to standardize the description and reporting of PGx 
variants. The group recommends the use of HGVS nomenclature to describe PGx variants 
and makes suggestions regarding the use of reference sequences, rs IDs and clinical 
reporting of variants and test descriptions. These recommendations are applicable to 
stakeholders including clinical laboratories and researchers who generate and report the 
results of PGx testing.
CONSENSUS RECOMMENDATIONS FOR STANDARDIZATION OF PGx 
(ADME) NOMENCLATURE
To address the standardization of PGx nomenclature, the Centers for Disease Control and 
Prevention (CDC) organized an international workgroup to review current PGx 
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nomenclature practices used to describe allelic variation of ADME PGx genes and facilitate 
translation between different nomenclature systems. Non-ADME genes, such as HLA, were 
excluded from the discussions. Ideas for mechanisms to increase the transparency of PGx 
test design were also discussed. Workgroup participants (summarized in Table 3) included a 
wide variety of stakeholders, many of whom also hold membership in relevant professional 
organizations and groups.
The workgroup held a series of conference calls and developed consensus recommendations 
for clinical and research laboratories to standardize PGx nomenclature and test result 
reporting. The workgroup discussed problems and needs in the following 5 areas: 1. 
Problems and limitations of the current PGx nomenclature systems; 2. Use of HGVS 
nomenclature to standardize and provide unambiguous descriptions of PGx variants; 3. 
Development of tools to assist transition from current PGx nomenclatures to HGVS; 4. Ideas 
to standardize and archive description of PGx assays in laboratory reports and electronic 
medical records; and 5. Development of a standardized panel of variants that should be 
included in PGx test panels. The workgroup decided to develop recommendations for the 
description and reporting of variants that could be applied to all PGx genes. Although topics 
related to the prediction and reporting of phenotype to physicians were not discussed, the 
issues addressed by the workgroup were considered relevant to current ability of clinical 
laboratories to accurately infer phenotypes from PGx test results. Consensus was determined 
by oral agreement by the majority of workgroup members.
Workgroup Recommendations
Current PGx nomenclature systems have been developed by domain experts, are widely 
accepted in PGx research communities, and have been commonly reported in the scientific 
literature. The workgroup agreed that the use of different nomenclature systems to describe 
PGx variants hinders communication and is not intuitive to clinicians, patients or researchers 
outside of the field. The group also acknowledged that PGx variants would be better 
reported in the context of the human genome assembly (as is the case with most non-PGx 
genes), especially as NGS applications are becoming more common. Because the current 
nomenclature is widely used in the PGx community, the workgroup did not recommend 
creating new nomenclature systems or abandoning current ones. Instead, they preferred to 
facilitate harmonization by clarifying sequence definitions of alleles. The workgroup 
recommended utilization of the Human Genome Variation Society nomenclature (27) for 
describing variants and haplotypes, and requiring transparency when reporting test results 
and describing underlying test methodologies. The workgroup suggested that for continuity 
and consistency with the literature, laboratories could also report star (*) alleles, or other 
legacy nomenclature, possibly as a side note on a report.
The following 9 recommendations (summarized in Table 4) take advantage of universally 
recognized and utilized systems for describing allelic variation.
Recommendations for naming sequence variants (recs 1-4):
1. Use HGNC nomenclature to specify the gene.
2. Report variants using HGVS variant nomenclature.
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3. Use a Locus Reference Genomic (LRG), RefSeqGene and/or a specific Human 
Genome Reference Assembly as a reference sequence. Both the reference sequence 
accession number and version number of the sequence should be indicated.
4. Report rs IDs from dbSNP, when available.
The workgroup recommended utilizing widely accepted systems that are already in place for 
human genes, in particular the HGNC gene nomenclature (48, 49), HGVS nomenclature and 
the Human Genome Reference Assembly (50). This will allow for transparent reporting of 
PGx variants to the clinical and research communities, facilitating incorporation of the data 
into existing human variation databases such as ClinVar and LOVD in a standardized 
manner. Use of fully qualified (reference sequence accession and version number indicated) 
HGVS nomenclature is recommended for submission of data to ClinVar as well as other 
databases.
The workgroup discussed ways to facilitate transition to the HGVS format from other 
nomenclature systems. The HGVS system requires description of variants relative to a 
reference sequence, which should be selected based on ability to support explicit (rather than 
inferred) representation, stable public access, comprehensiveness, and ease of use. Genomic 
sequences are recommended because intronic locations can be represented unambiguously. 
However, the exact genomic coordinates of such sequences are frequently updated as new 
information about the human genome is incorporated into the updated Human Genome 
Reference Assembly. These changes are versioned, and may alter the HGVS name of a 
variant which could cause confusion when results are compared over time. In order to 
reduce such misunderstandings, laboratories can include the latest HGVS nomenclature and 
the familiar or alternative names for the same variant in parenthesis.
The workgroup recognized that the genomic coordinates of the Human Genome Reference 
Assembly can be long, tedious and require noting the accession version number. Due to 
these challenges, the group recommended that HGVS notations could be made using a 
Locus Reference Genomic (LRG) (51, 52) or RefSeqGene sequence (53) as the reference. 
LRG sequences are stable genomic reference sequences of clinically important genes. LRG 
sequences do not change, even when new versions of the Human Genome Reference 
Assembly are adopted; this allows for a constant and unambiguous reference, a stable 
variant nomenclature, and shorter, more practical, coordinate values. LRG sequences are not 
currently available for a number of clinically actionable genes, but their creation is 
encouraged. Investigators from different domains of PGx research may thus consider 
requesting the creation of LRG sequences for specific PGx genes of interest in agreement 
with community consensus.
RefSeqGene sequences, which are similar to LRGs, can also be used as reference sequences. 
RefSeqGene and LRG are tightly coordinated, and when an LRG is created it is equivalent 
to a version of a RefSeqGene. Chromosome sequences from the Human Genome Reference 
Assembly, and gene-specific sequences from RefSeqGene are based on the current version 
of the human genome assembly. RefSeqGenes and chromosome sequences are updated and 
versioned as novel genomic information becomes available; thus the version number must 
be reported for the unambiguous definition of these sequences.
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Inclusion of dbSNP (54) reference SNP cluster identifiers (rs ID), each of which 
corresponds to a variant in a specific genomic location also provides a definition of each 
variant and allows reference to databases such as PharmGKB and ClinVar. rs IDs are 
available for the majority of commonly tested PGx variants and can be created upon request 
(55). In some cases, the variant described by the rs ID can refer to more than one sequence 
variant and may result in more than one haplotype designation. For example, the triallelic 
SNP rs5030865 (NG_008376.3:g.5959G>T, NM_000106.5:c.505G>T; NG_008376.3:g.
5959G>A, NM_000106.5:c.505G>A), defines haplotypes CYP2D6*8 and CYP2D6*14 
depending on whether the coding strand G>T or G>A substitution occurred. Hence, the 
HGVS annotation must also be stated to provide an unambiguous description.
Recommendation for naming variants (rec 5):
5 Use haplotype translation tables to convert star (*) alleles or other legacy 
nomenclature to fully-specified HGVS nomenclature for each variant in the 
haplotype.
Naming a variant using HGVS can be time consuming and any one of many reference 
sequences can be used, resulting in a large number of possible names for a given variant. 
The workgroup developed a series of tables based on the haplotype definition tables hosted 
by PharmGKB, which can be used to convert the star or other nomenclature to HGVS in a 
standardized manner, as shown in Figure 3. These conversion tables are available as 
“Reference Haplotype” lists on the Leiden Open Variation database 3.0 website (43). The 
tables provide the HGVS nomenclature of each rs ID variant using the Human Genome 
Reference Assembly, the RefSeqGene sequence, and LRG when available. They allow for 
easy and standardized naming of variants of known PGx haplotypes using HGVS. Similar 
tables will have to be developed for other commonly tested PGx genes in order to create a 
uniform system. HGVS nomenclature for variants with rs IDs is also provided by the 
ClinVar database and can be generated using the Mutalyzer SNP converter tool (56, 57). 
The nomenclature provided by Mutalyzer may need adjustment if the rs ID can refer to more 
than one variant, as described above. When pharmacogenetic genotypes are submitted to 
databases like ClinVar and LOVD, the HGVS expression for the genotype (e.g. 
combinations of haplotypes or rsSNPs) will also be provided in chromosome, RefSeqGene 
and LRG coordinates.
Recommendations for the test report (recs 6-9):
6 Indicate each variant and/or haplotype observed in the test report.
7 List variants and haplotypes that can be detected by the test (specific sites for 
genotyping tests, or regions for sequencing-based tests).
8 Describe the test, including limitations such as types of variants that cannot be 
detected.
9 The test description should be made publicly available on the laboratories’ 
website, and/or by registration of the test in the NIH Genetic Testing Registry 
(GTR).
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It is important to record not only the genotype determined for the patient, but also the exact 
variants and haplotypes that were tested. Current tests for PGx genes vary considerably 
between clinical and research laboratories. Hence alleles/haplotypes are often called based 
on different combinations of tested variants. Without a common understanding of which 
sequence variants are tested and which were found to be non-reference (variant), it is 
difficult to comprehend the meaning of a genotype result and compare genotypes reported 
by different laboratories or research studies.
The content of clinical test reports is specified by regulatory agencies and professional 
guidelines (58-63). The reports should include information such as patient name, name/
address of testing laboratory, test report date, test performed, test results, interpretation and 
other information as required by local regulations. Clinical laboratories in the United States 
are required to provide, when requested, a description of the test, the established 
performance specifications, and technical limitations (58, 61). Ideally, this information 
should be provided in the test report given to clinicians (59), although this is not mandatory 
and does not always occur.
Interpretation of PGx test results requires consideration of all variants that were tested. 
Because PGx haplotypes may be composed of one or more variants on the same 
chromosome, it is important to know which variants were tested and found in the sample 
and which were not. Laboratories typically report only those variants that were identified in 
a sample, because listing results for all variant loci tested would require a much larger report 
format. Descriptions of the variants included in a test are needed for result interpretation 
when the patient is tested initially and also if the test result will be used for future patient 
care decisions. It is important to archive the test description, since this information might not 
be transmitted to electronic medical records.
The unambiguous delineation of tested variants is supported by the GTR (14). By registering 
a genetic test in the GTR and reporting specific variants that are assayed by the test, a report 
generated for that test can provide a permanent record of what was assayed and therefore 
what variants were (or were not) explicitly detected. GTR provides a stable identifier 
(accession) which can be hyperlinked on the test report to the GTR website describing the 
test details such as methodology, indications/conditions, targets (genes; variants), test 
performance characteristics, limitations, and laboratory and test certifications. Next 
generation sequencing methodology has the capability to detect many, but not all variants 
within the genomic region(s) sequenced. It would not be feasible to list all variants that are 
potentially detectable by an NGS test; however those variants that are key determinants of a 
haplotype should be itemized to support transparency and reinterpretation. Thus, 
mechanisms such as GTR, which supports review of a test result by providing information 
on what alleles were potentially detectable by the assay and therefore what haplotypes have 
or have not been excluded, can inform the interpretation and resolution of discordant test 
results on the basis of assay capability. Furthermore, the test description within the GTR 
improves standardization and facilitates comparison of different tests based on test method 
and detectable variants.
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The workgroup also discussed the importance of clearly stating in the report which rs IDs or 
genomic regions, as well as other variant types such as copy number variants, the test is 
designed to detect, how the alleles/haplotypes are determined, and which variants were 
successfully tested in the specific analyses. In addition to highlighting the variants that are 
covered by the test, laboratories should also clearly describe the limitations of the test, 
possibly including clinically relevant variants, haplotypes and variant types, such as CNV, 
that cannot be detected. This information could be included in the “assay limitations” 
section of the laboratory report or included in a footnote or appendix. It is also important to 
state assay limitations related to haplotypes that cannot be differentiated due to variant 
phasing or test design. Information about test design and limitations should also be made 
publicly accessible. Laboratories may want to consider adding a disclaimer to the report 
stating that observed phenotype may be different than what is predicted based on the 
genotype due to the presence of untested variants, drug interactions or other genetic and 
environmental factors.
The workgroup discussed whether laboratories should consider reporting genotypes for loci 
that were tested but found to be non-variant (i.e. report genotypes for reference sequence at 
all non-variant but tested locations). This information is crucial for understanding how the 
reported haplotypes were determined, which haplotypes cannot be excluded, and the 
limitations of the test. It may be possible to simplify these data by providing the results of all 
rsSNPs and other variant types, such as CNVs, that can be detected by the test and are found 
to be non-reference and then stating in the report that all other rsSNPs and variants that can 
be detected by the test (and listed in the test description) were found to be non-variant 
(reference). This information could be provided in a footnote or as an appendix to the report. 
Variants should be described using HGVS nomenclature, preferably referenced to 
RefSeqGene or LRG coordinates as stated above.
This detailed description of the test should inform clinicians and other professionals (current 
and future) about the capabilities and limitations of the test to allow full evaluation and 
comprehension of the test results. The workgroup recognized that although it may not be 
feasible to list all possible variants and haplotypes that cannot be identified by the test, some 
context should be given to the results so that they can be interpreted and used for care of the 
patient in the future.
Additional Considerations
There are a number of challenges that must be addressed and overcome before many of 
these recommendations can be implemented. LRG sequences need to be designated for all 
relevant PGx genes. Identification of a reference sequence for many of these genes can be 
difficult because of their highly polymorphic nature and substantial differences between 
populations. For example, for the VKORC1 variant rs9923231 (NG_011564.1: g.3588G>A, 
NM_206824.1: c.-1639G>A), A is the major allele in East Asians but G is the more 
common allele in other population groups. Thus, it is difficult to decide which one should be 
designated as the reference sequence for this gene, complicating LRG assignment.
The NCBI has multiple databases that provide identifiers for variant locations and specific 
alleles. The dbSNP assigns an rs ID to locations where variants less than 50 bp have been 
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seen in one or more genomes. Ideally, the rs ID defines a unique genomic location. It is 
convenient to reference common PGx variants using the rs ID, however, caveats do exist. 
Some rsSNPs map to more than one genomic location because of sequence similarities, such 
as to a pseudogene or a functional gene within a family; therefore, the location of the variant 
being interpreted must be established. Also, not all variants, such as duplications, deletions 
or gene conversions that are larger than 50 base pairs are captured by dbSNP. Thus, other 
resources, such as dbVar (64), may also be used. The NCBI variation databases encourage 
feedback by a variety of stakeholders, including clinical laboratories, to prevent ambiguous 
variant descriptions based on its identifiers.
In PGx, it is critical to know which variants were identified and which were tested but found 
to be non-variant (i.e. wild-type, reference). In the example shown in Table 2, Laboratory 5 
could not distinguish a VKORC1*1 from a *3 or *4, because it only tested for rs9934438. 
This may have been apparent if the laboratory report had indicated the result from each 
tested rsSNP. Although listing this information could make patient test reports very long, it 
provides transparency to the test and its interpretation. This information could be included as 
a supplement or hyperlink to the laboratory’s current patient test report to keep the report 
brief.
Details about the test, including alleles tested and test limitations should be included in the 
electronic medical/health record (EMR/EHR) together with the patient’s results. As of 2015, 
some EMRs/EHRs can store the test results, but not the test description, as structured data. 
The test description is usually provided as unstructured text (often in pdf format) as part of 
the laboratory test report, which may be available electronically or as a paper copy. In some 
cases, only the predicted phenotype is reported when results are shared with other 
laboratories. The storage and display of genetic testing results is currently being addressed 
by a number of groups, including the Institute of Medicine (IOM) Action Collaborative 
DIGITizE: Displaying and Integrating Genetic Information Through the EHR (65) and the 
Electronic Medical Records and Genomics (eMERGE) Network (66).
PGx test standardization, a “Recommended Test Panel”?
As discussed above, the variants included in clinical PGx tests are not standardized. Without 
exception, no two tests that examined a particular PGx gene included in the GeT-RM study 
detected the same set of variants and/or haplotypes (39). In addition, some tests used 
different combinations of variants to define the haplotypes, leading to discrepancies between 
platforms in the reported genotype of many samples. Differences in test design, including 
inconsistent inclusion of variants and/or gene copy number detection, may impact allele 
calling, genotype assignment and ultimately test interpretation. The workgroup 
recommendations presented above assist in elucidating the differences between tests, but do 
not prevent them from occurring.
The variants tested and methods utilized to assign haplotypes would also need to be 
standardized to ensure that different tests provide consistent results. The nomenclature 
workgroup discussed the possible creation of a list of variants that should be tested, at a 
minimum, for clinically relevant PGx genes, analogous to the standardization of cystic 
fibrosis (CF) carrier screening. In 2001 and 2004, the American College of Medical 
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Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) 
developed a panel of 23 mutations that are recommended for CF carrier screening in the US 
population (67-69). Cystic fibrosis carrier screening assays offered by clinical laboratories 
typically include other alleles in addition to the 23 recommended CF alleles (15). Adoption 
of the ACOG/ACMG carrier panel has helped to standardize CF carrier testing and make the 
development and evaluation of assays more transparent.
“Recommended Test Panels” could be developed for clinical PGx assays, which may 
similarly help to standardize pharmacogenetic testing. SNVs/alleles for each gene could be 
selected using criteria such as population frequency, level of supporting evidence for 
phenotypic outcome, clinical utility and severity of adverse drug reaction. For example, a 
well-validated four-SNV set of rs1801280 (NG_012246.1:g.14100T>C, NM_000015.2:c.
341T>C), rs1799930 (NG_012246.1:g.14349G>A, NM_000015.2:c.590G>A), rs1799931 
(NG_012246.1:g.14616G>A, NM_000015.2:c.857G>A), and rs1801279 (NG_012246.1:g.
13950G>A, NM_000015.2:c.191G>A) is considered sufficient for prediction of the fairly 
common (70) poor metabolizer *5, *6, *7, and *14 allelic groups respectively of the NAT2 
gene according to the current nomenclature (71). On the other hand, complete DPYD 
deficiency is considered relatively rare (<1%) with estimates of the frequency of the *2A 
allele (the most common variant associated with DPYD deficiency) ranging from <0.005 to 
3.5% in different populations. Since patients who are homozygous for DPYD*2A are at 
highest risk for severe or even fatal 5-fluorouracil or capecitabine toxicity, use of both drugs 
is not recommended for these patients (72). Thus, although these variants are very rare, the 
severity of the adverse reaction would justify inclusion in the “Recommended Test Panel” 
for DPYD.
Standardized panels would enable physicians, pharmacists, researchers and other 
stakeholders to understand PGx test results without extensive scrutiny of the alleles included 
in the assay, and would provide assurance that the panels include a core set of variants 
considered most important for clinical utility. This is especially important when test results, 
originally obtained to assist selection and dosing of one drug, are later used for selection and 
dosing of a different drug for the same patient. Assays would be directly comparable and 
yield comparable results for the same sample. As with CF, laboratories could add additional 
alleles to their assays for research and other purposes.
The workgroup members did not reach consensus regarding the feasibility of creating PGx 
“Recommended Test Panel” lists. While all acknowledged the clear benefits of having such 
panels, many felt that such an undertaking fell outside of the scope of this particular 
workgroup. The European Pharmacogenetic Implementation Consortium (73), a workgroup 
of the IFCC, is currently developing a list of PGx alleles that should be included in clinical 
tests. It can be argued that determining a “Recommended Test Panel” for pharmacogenes is 
even more difficult than for Mendelian diseases. Additionally, allele function in in vitro 
models may not be equivalent to clinical phenotype, and allele function can be substrate 
(drug), or drug concentration-dependent. Although an allele can be extremely rare in the 
general population, it can be frequent in another population or in a phenotypically selected 
group of patients (e.g. those with side effects on specific drugs). Therefore, the question 
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arises, if the allele is rare, but unequivocally affects function, should it be included in a test 
panel?
Additionally, a “Recommended Test Panel” would require periodic re-evaluation as novel 
variants are found, characterized and new insights into genotype-phenotype relationships are 
identified. Each association will need to be evaluated by the same criteria to assess 
importance and added to the “Recommended Test Panel” if the criteria are met. In some 
cases, further research may show that an allele previously on the “Recommended Test 
Panel” list no longer meets the required criteria. A plan for routine evaluation of 
“Recommended Test Panel” would be critical.
Conclusion and Future Plans
The PGx Nomenclature Workgroup has developed recommendations to standardize the way 
pharmacogenetic variants are described and reported. These recommendations, together with 
those currently being developed to standardize phenotype inference (74), will make PGx test 
results more transparent and will harmonize PGx testing with the broader field of genetic 
testing.
One important aim of this manuscript is to link existing, non-standard variant descriptions 
and reporting to existing standards like the HGVS nomenclature (28). Clinicians and others 
who are familiar with the star nomenclature might find the HGVS nomenclature to be 
tedious or hard to understand. To address this issue, the workgroup suggests that laboratory 
reports can include common or familiar names in parenthesis along with the HGVS notation. 
In addition, this group is currently developing HGVS conversion tables for pharmacogenes 
that will allow easy translation between the recommended nomenclature and those notations 
currently in use.
The workgroup is proposing these changes with the expectation that they will be considered 
by organizations including gene variation databases, scientific journals, regulatory agencies, 
and professional societies for the creation of policies, guidelines and recommendations. 
Following publication of these recommendations, the workgroup plans to meet with 
representatives of relevant professional societies, PGx gene nomenclature committees, and 
other groups, some of whom have begun to address these issues to explore these ideas 
further.
The workgroup hopes that these proposed recommendations will be discussed and ultimately 
adopted by the PGx community. Although some ideas described may appear controversial, 
these recommendations are intended to lead to a more standardized approach to testing and 
reporting of PGx test results. Ultimately, standardization will enhance clinical interpretation 
of PGx associations, accelerating the implementation of pharmacogenetics into routine 
clinical practice.
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Figure 1. 
Reference sequence and genotype calls for one representative variant of the ABCB1 gene 
(rs1045642). Genomic DNA was tested using NGS by five laboratories as part of a GeT-RM 
study. The result from one sample (HG00276) is shown. Reference indicates the rs1045642 
sequence against which the test sample was called. As shown, the sample was heterozygous 
for rs1045642, but was reported as C/T when C was used as reference and A/G when A 
served as reference. The test result, i.e. the detection of heterozygosity, was accurately 
achieved by all five laboratories; however, the actual reporting against different reference 
sequences is difficult to interpret.
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Figure 2. 
CYP2C19*2, *4, and *17 alleles are used to illustrate how metabolizer phenotypes will be 
miscalled if CYP2C19*2 and *17 but not CYP2C19*4, are tested. Four possible scenarios 
are shown (Cases A-D). Panel A shows the phenotypes based on testing the key SNVs for 
CYP2C19*2 and *17. Panel B shows the phenotypes based on testing the key variants for 
CYP2C19*2, *4 and *17. Phenotypes shown in red in Panel B would have been miscalled if 
rs28399504 is present in the sample, but not included in the assay. These alleles are used as 
example, demonstrating that all alleles affecting CYP2C19 functionality should be 
interrogated in order to accurately call phenotypes. (PM = poor metabolizer; IM = 
intermediate metabolizer; EM = extensive metabolizer; UM = ultrarapid metabolizer)
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Figure 3. 
Example of a tool that can be used to convert between star allele and HGVS nomenclature 
for CYP2C19. Panel A. Portion of a haplotype - HGVS conversion table for CYP2C19. 
Coordinates from the Human Genome Reference Assembly [e.g. NC_000010.10 (GRCh37), 
NC_000010.11 (GRCh38)], RefSeqGene (NG_008384.2), reference transcript 
(NM_000769.2), and reference protein (NP_000760.1) are provided for each of the rs IDs 
indicated, as applicable. An LRG sequence is not currently available for this gene. The 
relative exonic location of each rsSNP is indicated. The haplotype status of each rsSNP is 
indicated as nonvariant (black font in the reference *1 haplotype) or variant (red font in the 
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polymorphic haplotypes). The combination of variants that compose each haplotype is also 
shown. Cells with gold shading indicates the defining SNP for each haplotype. Cells with 
red shading indicates rsSNPs with more than one possible variant nucleotide. HGVS 
nomenclature was derived from the dbSNP rs ID using the Mutalyzer SNP Converter tool 
(https://www.mutalyzer.nl/). Panel B. Detail of CYP2C19 haplotype - HGVS conversion 
table showing variants defining CYP2C19*4, *4A and *4B haplotypes.
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Table 1
Examples of public PGx gene or gene family haplotype databases
Gene or gene family Resource URL
Cytochrome P450 enzymes Human Cytochrome P450 (CYP) Allele 
Nomenclature Database*
http://www.cypalleles.ki.se/
Cytochrome P450 enzymes SuperCYP http://bioinformatics.charite.de/supercyp/
UGT UDP-Glucuronosyltransferase (UGT) nomenclature http://www.pharmacogenomics.pha.ulaval.ca/cms/ugt_alleles/
TPMT Thiopurine methyltransferase (TPMT) 
Nomenclature
http://www.imh.liu.se/tpmtalleles?l=en
NAT Arylamine N-acetyltransferase (NAT) Allele 
Nomenclature Database
http://nat.mbg.duth.gr
HLA HLA Nomenclature http://hla.alleles.org/nomenclature/index.html
*Sim, S.C. & Ingelman-Sundberg, M. Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-
allele) Nomenclature Database. Methods in molecular biology 987, 251-9 (2013).
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Table 3
Groups, organizations and stakeholders represented by the Workgroup members
Pharmacogenetics community:
• Pharmacogenomics Knowledge Base (PharmGKB)
• Pharmacogenomics Research Network (PGRN)
• Clinical Pharmacogenetics Implementation Consortium (CPIC)*
• European Pharmacogenetic Implementation Consortium (Eu-PIC)
• Ubiquitous Pharmacogenomics (U-PGx)
• European Society for Pharmacogenomics and Personalized Therapy (ESPT)
• International Federation for Clinical Chemistry (IFCC) Task Force –Pharmacogenetics
• ClinGen PGx Working Group
Regulatory/Governmental Agencies:
• Food and Drug Administration (FDA)**
• European Medicine Agency (EMA) PGx Working Group
• College of American Pathologists (CAP)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
Genetic Nomenclature Committees:
• HUGO Gene Nomenclature Committee (HGNC)
• Human Genome Variation Society (HGVS)
Gene Variant Databases:
• National Center for Biotechnology Information (NCBI)
• ClinVar
• Genetic Testing Registry (GTR)
• RefSeqGene
• MedGen
• European Bioinformatics Institute (EBI)
• Locus Reference Genomic (LRG)
• Leiden Open Variation Database (LOVD)
PGx Gene Specific Nomenclature Committees and Databases:
• Human Cytochrome P450 (CYP) Allele Nomenclature Database
• UDP-Glucuronosyltransferase (UGT) Alleles Nomenclature Page
• Thiopurine methyltransferase (TPMT) Nomenclature Committee
• Arylamine N-acetyltransferase (NAT) Gene Nomenclature Committee
Professional societies and Standards Development Organizations:
• International Federation for Clinical Chemistry (IFCC)
• Association for Molecular Pathology (AMP)
• HL7 Clinical Genomics Working Group
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PGx test developers
Clinical and research laboratories
*Caudle, K.E. et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) guideline development process. Current drug metabolism 15, 209-17 (2014)
**
FDA supports efforts towards PGx nomenclature standardization but the use of standardized nomenclature is not currently a regulatory 
requirement for clearance or approval of in vitro diagnostic tests.
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Table 4
Summary of International Workgroup Recommendations
Naming Sequence Variants:
1 Use HGNC nomenclature to specify the gene.
2 Report variants using HGVS nomenclature.
3 Use Locus Reference Genomic (LRG), RefSeqGene, and/or a specific Human Genome Reference Assembly as a reference 
sequence. Both the reference sequence accession number and version number of the sequence should be indicated.
4 Report rs IDs from dbSNP, when available.
5 Use haplotype translation tables to convert star (*) alleles or other legacy nomenclature to fully-specified HGVS nomenclature for 
each variant in the haplotype.
Test Report:
6 Indicate each variant and/or haplotype observed in the test report.
7 List variants and haplotypes that can be detected by the test (specific sites for genotyping tests, or regions for sequencing-based 
tests).
8 Describe the test, including limitations such as types of variants that cannot be detected.
9 The test description should be made publicly available on the laboratories’ website, and/or by registration of the test in the NIH 
Genetic Testing Registry (GTR).
Clin Pharmacol Ther. Author manuscript; available in PMC 2017 February 01.
